Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Propranolol
Drug ID BADD_D01867
Description Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors.[L6904] Propranolol is used to treat a number of conditions but most commonly is used for hypertension.[L6901,L6904,L6907] Propranolol was granted FDA approval on 13 November 1967.[L6904]
Indications and Usage For the prophylaxis of migraine.
Marketing Status Prescription; Discontinued
ATC Code C07AA05
DrugBank ID DB00571
KEGG ID D08443
MeSH ID D011433
PubChem ID 4946
TTD Drug ID D04JEE
NDC Product Code Not Available
Synonyms Propranolol | Propanolol | Inderal | Avlocardyl | AY-20694 | AY 20694 | AY20694 | Rexigen | Dexpropranolol | Dociton | Obsidan | Obzidan | Propranolol Hydrochloride | Hydrochloride, Propranolol | Anaprilin | Anapriline | Betadren
Chemical Information
Molecular Formula C16H21NO2
CAS Registry Number 525-66-6
SMILES CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionCytochrome P450 2D6P10635T57392Not Available
BradycardiaCytochrome P450 3A4P08684T3784812864757; 15209687; 11999139
BradycardiaCytochrome P450 3A4P08684T3784816634720; 7594046; 8245337; 16770596; 10825413; 7694600
HypotensionCytochrome P450 3A4P08684T3784812864757; 15209687; 11999139
HypotensionCytochrome P450 3A4P08684T3784816634720; 7594046; 8245337; 16770596; 10825413; 7694600
Mitochondrial toxicityCa2+/Mg2+ ATPaseQ63080Not Available3157382; 6324685; 2996181; 7994564; 6713449; 10370869; 2938592; 12498738; 2630100; 6316993
Poisoning and toxicityCytochrome P450 2D6P10635T57392Not Available
Poisoning and toxicityCytochrome P450 1A1P04798Not Available15094323; 11906967; 15224175
Sudden cardiac deathPotassium voltage-gated channel subfamily H member 2Q12809T202519927398; 10810773; 10082151; 10408028
Sudden cardiac deathPotassium voltage-gated channel subfamily KQT member 1P51787T495269927398; 10810773; 10082151; 10408028
Sudden cardiac deathSodium channel protein type 5 subunit alphaQ14524T397169927398; 10810773; 10082151; 10408028
Sudden cardiac deathPotassium voltage-gated channel subfamily E member 1P15382Not Available9927398; 10810773; 10082151; 10408028
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Myotonia17.05.02.013; 15.05.04.013--Not Available
Blood disorder01.05.01.004--Not Available
Respiratory syncytial virus infection22.07.02.002; 11.05.13.0010.001519%Not Available
Disease recurrence08.01.03.0500.000760%Not Available
Drug intolerance08.06.01.0130.001899%Not Available
Psychotic disorder19.03.01.0020.001013%
Pulmonary toxicity22.01.02.007; 12.03.01.0130.000760%Not Available
Urine analysis abnormal13.13.02.0080.000253%Not Available
Respiratory tract infection22.07.07.001; 11.01.08.0170.000380%Not Available
Unevaluable event08.01.03.051--Not Available
Poor quality sleep19.02.05.005; 17.15.04.0020.000886%Not Available
Increased bronchial secretion22.02.04.0070.000253%Not Available
Arterial insufficiency24.04.02.005--Not Available
Peripheral arterial occlusive disease24.04.03.010--Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.000886%Not Available
Dark circles under eyes06.08.03.019; 08.01.03.0540.000253%Not Available
Chronic kidney disease20.01.03.017--
Neuropsychological test abnormal13.07.06.001--Not Available
Treatment failure08.06.01.0170.000495%Not Available
Liver injury12.01.02.003; 09.01.07.0220.000380%Not Available
Regurgitation07.01.07.0040.000253%Not Available
Oropharyngeal discomfort07.05.05.008; 22.02.05.027--Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.0040.001139%
Mechanical urticaria10.01.06.004; 23.04.02.0040.000253%Not Available
Acute kidney injury20.01.03.016--
Hypoxic-ischaemic encephalopathy24.04.06.021; 22.02.02.011; 17.13.02.0060.000066%Not Available
Foetal growth restriction18.03.01.0020.000886%
Substance-induced psychotic disorder19.03.01.007; 12.03.01.0530.000886%Not Available
Hepatocellular carcinoma16.07.02.005; 09.04.02.010--Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.021--Not Available
The 15th Page    First    Pre   15 16    Next   Last    Total 16 Pages